EDAP TMS (NASDAQ:EDAP) is a global medical device company specializing in non-invasive therapeutic ultrasound technologies. The company develops, manufactures and markets systems designed to treat prostate cancer and urological conditions through high-intensity focused ultrasound (HIFU) and extracorporeal shock wave lithotripsy. EDAP’s solutions are intended to provide precise, targeted therapy with reduced recovery times and minimal side effects compared to traditional surgical approaches.
EDAP’s oncology portfolio centers on its Focal One® and Ablatherm® HIFU platforms, which use real-time imaging guidance to ablate prostate tissue. Focal One is engineered for focal therapy, potentially limiting treatment to cancerous regions and preserving healthy tissue, while Ablatherm offers whole-gland ablation. In urology, the company’s Litho® series employs lithotripsy to fragment kidney stones using acoustic shock waves, with models such as Sonolith® i-moved designed for mobile and hospital settings. EDAP continually invests in R&D to enhance workflow, imaging precision and patient comfort across its product lines.
Founded in Lyon, France, in 1979, EDAP TMS has grown from its initial focus on extracorporeal lithotripsy into a multi-segment medical technology enterprise. The company established its U.S. subsidiary in the early 1990s and has since achieved regulatory clearances from bodies including the U.S. Food and Drug Administration and the European CE mark. EDAP’s commercial network spans North America, Europe, Latin America and Asia, partnering with leading hospitals, cancer centers and specialist practitioners to broaden access to its minimally invasive treatments.
Under the leadership of Chief Executive Officer Stephan H. Conrad, EDAP TMS emphasizes clinical collaboration and evidence-based practice to drive adoption of its technologies. The management team comprises industry veterans in medical device development, regulatory affairs and global sales. Through strategic alliances and ongoing clinical trials, EDAP aims to expand indications for its therapeutic ultrasound platforms while maintaining a focus on patient outcomes, operational efficiency and sustainable growth in emerging and established markets alike.
AI Generated. May Contain Errors.
